Karin Smyth

It is a pleasure to serve under you chairship, Dr Allin-Khan. I am grateful for the opportunity to address the House following the second anniversary of the report by the Patient Safety Commissioner, Dr Henrietta Hughes. I pay tribute to her work and, as others have, to Baroness Cumberlege for her work in the lead-up to that report. I also thank the hon. Member for Chesham and Amersham (Sarah Green) for securing this important debate. It has been a thoughtful and constructive debate on an issue that is highly sensitive for Members across the House, for campaigners and people who are here today, and for people watching online. To answer the question from the hon. Member for Sleaford and North Hykeham (Dr Johnson), I am responding to this debate on behalf of the Under-Secretary of State for Health and Social Care, my hon. Friend the Member for Glasgow South West (Dr Ahmed). He is the lead Minister for this area, but unfortunately cannot be here today—as Members will understand, that is often an issue, but I am happy to stand in. This is a matter of great interest to him personally. As colleagues know, he is a clinician, so has valuable insight into patient safety and how it works from a clinical perspective. My hon. Friend wanted me to be clear that he is very happy to meet campaigners, as the hon. Member for Chesham and Amersham asked, to discuss our work in more detail. He met the Patient Safety Commissioner in December to discuss the Department’s ongoing work in relation to her report. Since then, he has continued his engagement with the commissioner on how we can do more to address the immediate needs of those affected by sodium valproate and pelvic mesh. As we have heard, and as many of us know from constituents—I know that many other Members have affected constituents but were not able to attend the debate—some of these women’s lives, as well as those of their families, have been changed forever because they were misled about the effects of sodium valproate and surgical mesh. Many examples have been given in the debate, and constituents of mine have shared the most intimate details of the impact of sodium valproate and pelvic mesh. It has been truly harrowing for me and many other Members to listen to those details, as I am sure it was for those women who bravely shared them with a stranger, their Member of Parliament. That point was made well by many Members, including my hon. Friend the Member for Rushcliffe (James Naish), the hon. Member for Frome and East Somerset (Anna Sabine), and the Liberal Democrat spokesperson, the hon. Member for South Devon (Caroline Voaden), who spoke on behalf of her constituents. We owe honesty, transparency and contrition to all the women affected, and we are determined to make sure that the lessons are learned and to keep patient safety at the heart of the reform. My hon. Friend the Member for Wolverhampton West (Warinder Juss) rightly highlighted the issue of trust in the system, which is so important as we go forwards. Our focus remains on building a system that listens and that acts with speed, compassion and proportionality. Everybody who has suffered complications from sodium valproate and pelvic mesh implants has my deepest sympathies. I express my gratitude to Dr Hughes and her team for the report that was published two years ago, and I am grateful, too, for her continued engagement with the Department as Patient Safety Commissioner.